Head-To-Head Survey: DENTSPLY SIRONA (XRAY) versus Haemonetics Corporation (NYSE:HAE)

Haemonetics Corporation (NYSE: HAE) and DENTSPLY SIRONA (NASDAQ:XRAY) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Dividends

DENTSPLY SIRONA pays an annual dividend of $0.35 per share and has a dividend yield of 0.7%. Haemonetics Corporation does not pay a dividend. DENTSPLY SIRONA pays out -10.1% of its earnings in the form of a dividend.

Profitability

This table compares Haemonetics Corporation and DENTSPLY SIRONA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Haemonetics Corporation	0.48%	11.07%	6.54%
DENTSPLY SIRONA	-20.57%	7.24%	5.02%

Earnings & Valuation

This table compares Haemonetics Corporation and DENTSPLY SIRONA’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
Haemonetics Corporation	$887.11 million	2.47	$164.54 million	$0.08	519.81
DENTSPLY SIRONA	$3.84 billion	3.16	$825.00 million	($3.47)	-15.23

DENTSPLY SIRONA has higher revenue and earnings than Haemonetics Corporation. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Haemonetics Corporation, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

95.1% of DENTSPLY SIRONA shares are held by institutional investors. 1.2% of Haemonetics Corporation shares are held by company insiders. Comparatively, 2.0% of DENTSPLY SIRONA shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Haemonetics Corporation has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Haemonetics Corporation and DENTSPLY SIRONA, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics Corporation	1	3	3	0	2.29
DENTSPLY SIRONA	1	2	8	0	2.64

Haemonetics Corporation currently has a consensus target price of $39.83, indicating a potential downside of 4.20%. DENTSPLY SIRONA has a consensus target price of $66.40, indicating a potential upside of 25.62%. Given DENTSPLY SIRONA’s stronger consensus rating and higher possible upside, analysts plainly believe DENTSPLY SIRONA is more favorable than Haemonetics Corporation.

Summary

DENTSPLY SIRONA beats Haemonetics Corporation on 11 of the 16 factors compared between the two stocks.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies. The dental industry encompasses the diagnosis, treatment and prevention of disease and ailments of the teeth, gums and supporting bone. Its principal dental product categories are dental consumable products, dental laboratory products, dental specialty products and dental equipment. Additionally, its consumable medical device products are used for urological and surgical applications. These products are produced by the Company in the United States and internationally and are distributed throughout the world under various brand names, including ANKYLOS, AQUASIL ULTRA, ARTICADENT, ATLANTIS, CALIBRA, CAULK, CAVITRON, CELTRA, DELTON, DENTSPLY, DETREY and DYRACT.